In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vanguard Medica buys CNS biotech Cerebrus

Executive Summary

Vanguard Medica (inlicenses early stage drugs) is buying Cerebrus (CNS therapeutics) in an all-stock transaction. Cerebrus shareholders will get 7.09mm Vanguard ordinary shares, valued at $15.37mm (UK9.6mm) at the time the deal was announced. After the merger Vanguard plans to change its name to Vernalis Group PLC.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies